An internal standard for the quantification of C18 ceramide
Related Products
Alternative(s)
24396C18 Ceramide-d3 (d18:1/18:0-d3)
Unlabeled Version(s)
19556C18 Ceramide (d18:1/18:0)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

C18 Ceramide-d7 (d18:1-d7/18:0)

Item No. 22788

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl-15,15,16,16,17,17,17-d7]-octadecanamide
CAS Number
1840942-14-4
Synonyms
  • C18 Ceramide-d7
  • Cer-d7 (d18:1-d7/18:0)
  • Ceramide-d7 (d18:1-d7/18:0)
  • N-Stearoyl-D-Sphingosine-d7
Molecular Formula
C36H64D7NO3
Formula Weight
573.0
Purity
≥99% deuterated forms (d1-d7)
Formulation
A 1 mg/ml solution in methanol:chloroform (10:90)
Solubility(Learn about Variance in Solubility)
DMF: 0.15 mg/ml
SMILES
OC[C@H](NC(CCCCCCCCCCCCCCCCC)=O)[C@H](O)/C=C/CCCCCCCCCCC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H]
InChi Code
InChI=1S/C36H71NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h29,31,34-35,38-39H,3-28,30,32-33H2,1-2H3,(H,37,40)/b31-29+/t34-,35+/m0/s1/i2D3,4D2,6D2
InChi Key
VODZWWMEJITOND-MUVBWDEFSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 µg

    $124

    Add

    250 µg

    $275

    Add

    500 µg

    $459

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    C18 Ceramide-d7 is intended for use as an internal standard for the quantification of C18 ceramide (Item No. 19556) by GC- or LC-MS. C18 Ceramide is an endogenous bioactive sphingolipid. It is the primary short-chain ceramide found in brain tissue whose synthesis is regulated by longevity-assurance homologue 1 (Lass1) in mice.1 Increased expression of C18 ceramide reduces cell growth in UM-SCC-22A squamous cell carcinoma cells.2 It is selectively down-regulated in 32 human head and neck squamous cell carcinoma tumor tissues as compared to non-squamous tumor tissues. C18 Ceramide concentration is significantly higher in muscle tissue of type 2 diabetic patients compared with non-diabetic patients and is positively correlated to body mass index and inversely related to insulin sensitivity.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Mizutani, Y., Kihara, A., and Igarashi, Y. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem J. 390(Pt. 1), 263-271 (2005).

    2. Koybasi, S., Senkal, C.E., Sundararaj, K., et al. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. The Journal of Biological Chemisty 279(43), 44311-44319 (2004).

    3. Bergman, B.C., Brozinick, J.T., Strauss, A., et al. Muscle sphingolipids during rest and exercise: A C18:0 signature for insulin resistance in humans. Diabetologia 59(3), 785-791 (2016).

    Product Citations

    Tagi, H., Qiu, C., Zeng, Y., et al. Serine supplementation suppresses hypoxia-induced pathological retinal angiogenesis. Theranostics 15(1), 5087-5105 (2025).